Claims for Patent: 6,713,086

Summary for Patent: 6,713,086

Title:	Controlled release formulation of divalproex sodium
Abstract:	A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.
Inventor(s):	Qiu; Yihong (Gumee, IL), Bollinger; J. Daniel (Libertyville, IL), Cheskin; Howard S. (Glencoe, IL), Dutta; Sandeep (Waukegan, IL), Engh; Kevin R. (Kenosha, IL), Poska; Richard P. (Mundelein, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	10/215,142
Patent Claims:	1. A oral polymeric controlled release formulation suitable for once-a-day administration comprising: a) from about 40 to about 80 w/w % of divalproex sodium; b) a pharmaceutically acceptable hydrophilic polymer in which said hydrophilic polymer is present in the quantity of from about 20% to about 50%, by weight of the formulation, and said hydrophilic polymer is selected from the group consisting of polyvinylpyrrolidine, hydroxypropyl cellulose, hydroxypropylmethyl celllose, methyl cellulose, vinyl acetate copolymers, polysaccharide, polyethylene oxide, methacrylic acid copolymers and maleic anhydride/methyl vinyl ether copolymers, and; c) when said formulation is ingested orally by healthy human subjects, said formulation produces a C.sub.max that is statistically significantly lower than the C.sub.max produced by an enteric coated delayed release divalproex sodium tablet given twice daily, when each is determined at steady state in a fasting population. 2. The formulation according to claim 1 which produces a C.sub.min that is not statistically significantly different from the C.sub.min produced by said delayed release divalproex sodium tablet, when each is determined at steady state in a healthy fasting population. 3. The formulation according to claim 1 in which said formulation produces an AUC value that is equivalent to the AUC value generated by said divalproex sodium delayed release tablet, when each is determined at steady state in a healthy fasting population. 4. The formulation according to claim 1 which: a) produces a C.sub.min in that is not statistically significantly different from the C.sub.min produced by said delayed release divalproex sodium tablet, when each is determined at steady state in a healthy fasting population, and; b) said formulation produces an AUC value that is equivalent to the AUC value generated by said divalproex sodium delayed release tablet, when each is determined at steady state in a healthy fasting population. 5. The formulation according to claim 4 which produces a degree of fluctuation that is lower than the degree of fluctuation produced said delayed release divalproex sodium tablet, when each is determined at steady state in a fasting population. 6. The formulation according to claim 1 in which said formulation is a matrix system, an osmotic pump system or a reservoir polymeric system. 7. A oral polymeric controlled release formulation suitable for once-a-day administration comprising: a) from about 40 to about 80 w/w % of divalproex sodium b) a pharmaceutically acceptable hydrophilic polymer in which said hydrophilic polymer is present in the quantity of from bout 20% to about 50%, by weight of the formulation, and said hydrophilic polymer is selected from the group consisting of polyvinylpyrrolidine, hydroxypropylcellulose, hydroxypropylmethyl cellulose methyl cellulose, vinyl acetate copolymers, polysaccharides, polyethyleneoxide, methacrylic acid copolymers and maleic anhydride/methyl vinyl ether copolymers and; c) when said formulation is ingested orally by healthy human-subjects, said formulation produces: i. a C.sub.max that is statistically significantly lower than the C.sub.max produced by an enteric coated delayed release divalproex sodium tablet given twice daily, when each C.sub.max is determined at steady state in a fasting population, ii. a C.sub.min that is not statistically significantly different from the C.sub.min produced by said delayed release divalproex sodium tablet, when each C.sub.min is determined at steady state in a fasting population, and; iii. said formulation produces an AUC value that is equivalent to the AUC value generated by said divalproex sodium delayed release tablet, when each AUC is determine at steady state in a fasting population. 8. The formulation according to claim 7 in which said formulation produces steady state peak plasma valproate levels that are about 10 to about 20% lower than that produced by a said delayed release divalproex sodium tablet. 9. A method for the treatment of migraine comprising the administration of a formulation according to claim 1 to a patient in need thereof. 10. A method for the treatment of epilepsy comprising the administration of a formulation according to claim 1 to a patient in need thereof. 11. A method for the reduction of side effects associated with divalproex sodium therapy comprising the administration of a formulation according to claim 1. 12. A oral polymeric controlled release formulation suitable for once-a-day administration comprising: a) from about 40 to about 80 w/w % of divalproex sodium; b) a pharmaceutically acceptable hydrophilic polymer in which said hydrophilic polymer is present in the quantity of from about 20% to about 50%, by weight of the formulation, and said hydrophilic polymer is selected from the group consisting of polyvinylpyrrolidine, hydroxypropyl cellulose, hydroxypropylmethyl celllose, methyl cellulose, vinyl acetate copolymers, polysaccharide, polyethylene oxide, methacrylic acid copolymers and maleic anhydride/methyl vinyl ether copolymers, and; c) when said formulation is ingested orally by healthy human subjects, said formulation produces a C.sub.max that is statistically significantly lower than the C.sub.max produced by an enteric coated delayed release divalproex sodium tablet given twice daily, when each is determined at steady state in a fasting population. 13. The formulation according to claim 3 which produces a C.sub.min that is not statistically significantly different from the C.sub.min produced by said twice daily dosage form when each is determined at steady state in a healthy fasting population. 14. The formulation according to claim 12 in which said formulation produces an AUC value that is equivalent to the AUC value generated by said bid valproate dosage form, when each is determined at steady state in a healthy fasting population. 15. The formulation according to claim 12 which: a) produces a C.sub.min that is not statistically significantly different from the C.sub.min produced by said bid valproate dosage form, when each is determined at steady state in a healthy fasting population, and; b) said formulation produces an AUC value that is equivalent to the AUC value generated by said bid valproate dosage form, when each is determined at steady state in a healthy fasting population. 16. The formulation according to claim 12 which produces a degree of fluctuation that is not statistically significantly different than the degree of fluctuation by produced the twice daily valproate dosage form, when each is determined at steady state in a fasting population. 17. The formulation according to claim 12 in which said formulation is a matrix system, an osmotic pump system or a reservoir polymeric system.